Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma

Simple item page
dc.contributor.authorCheong, C.M.
dc.contributor.authorMrozik, K.M.
dc.contributor.authorHewett, D.R.
dc.contributor.authorBell, E.
dc.contributor.authorPanagopoulos, V.
dc.contributor.authorNoll, J.E.
dc.contributor.authorLicht, J.D.
dc.contributor.authorGronthos, S.
dc.contributor.authorZannettino, A.C.W.
dc.contributor.authorVandyke, K.
dc.date.issued2020
dc.description.abstractApproximately 15% of patients with multiple myeloma (MM) harbour the t(4;14) chromosomal translocation, leading to the overexpression of the histone methyltransferase NSD2. Patients with this translocation display increased tumour dissemination, accelerated disease progression and rapid relapse. Using publicly available gene expression profile data from NSD2(high) (n=135) and NSD2(low) (n=878) MM patients, we identified 39 epithelial-mesenchymal transition (EMT)-associated genes which are overexpressed in NSD2(high) MM plasma cells. In addition, our analyses identified Twist-1 as a key transcription factor upregulated in NSD2(high) MM patients and t(4;14)-positive cell lines. Overexpression and knockdown studies confirmed that Twist-1 is involved in driving the expression of EMT-associated genes in the human MM cell line KMS11 and promoted the migration of myeloma cell lines in vitro. Notably, Twist-1 overexpression in the mouse MM cell line 5TGM1 significantly increased tumour dissemination in an intratibial tumour model. These findings demonstrate that Twist-1, downstream of NSD2, contributes to the induction of an EMT-like signature in t(4;14)-positive MM and enhances the dissemination of MM plasma cells in vivo, which may, in part, explain the aggressive disease features associated with t(4;14)-positive MM.
dc.description.statementofresponsibilityChee Man Cheong, Krzysztof M. Mrozik, Duncan R. Hewett, Elyse Bell, Vasilios Panagopoulos, Jacqueline E. Noll, Jonathan D. Licht, Stan Gronthos, Andrew C.W. Zannettino, Kate Vandyke
dc.identifier.citationCancer Letters, 2020; 475:99-108
dc.identifier.doi10.1016/j.canlet.2020.01.040
dc.identifier.issn0304-3835
dc.identifier.issn1872-7980
dc.identifier.orcidMrozik, K.M. [0000-0002-4890-8208]
dc.identifier.orcidPanagopoulos, V. [0000-0002-6879-1262]
dc.identifier.orcidNoll, J.E. [0000-0001-7375-635X]
dc.identifier.orcidGronthos, S. [0000-0002-6225-3084]
dc.identifier.orcidZannettino, A.C.W. [0000-0002-6646-6167]
dc.identifier.orcidVandyke, K. [0000-0002-1033-849X]
dc.identifier.urihttp://hdl.handle.net/2440/124746
dc.language.isoen
dc.publisherElsevier
dc.relation.grantNHMRC
dc.rights© 2020 Elsevier B.V. All rights reserved.
dc.source.urihttps://doi.org/10.1016/j.canlet.2020.01.040
dc.subjectMultiple myeloma; epithelial-mesenchymal transition; NSD2; Twist-1; dissemination
dc.titleTwist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications